TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26969631

Group type: EXPERIMENTAL
Intervention: Home-based transitional palliative care (weekly home visits/telephone calls for 4 weeks, then monthly follow-up)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Home-based transitional palliative care
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 84
Study: 25224756

Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) intervention
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PMTCT Option B
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard of care (Control)
Number of subjects: 60
Study: 22869826

Group type: EXPERIMENTAL
Intervention: Healthy media use intervention (replacing violent or age-inappropriate media with educational content)
Number of subjects: 565

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 565
Study: 20163429

Group type: EXPERIMENTAL
Intervention: 6-minute walk test (6MWT)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Timed Up and Go (TUG) test
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Functional Mobility Scale (FMS) scores
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Multiple regression analysis
Number of subjects: 126
Study: 18275370

Group type: EXPERIMENTAL
Intervention: Depressed individuals who attempted suicide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Depressed individuals who did not attempt suicide
Number of subjects: 0
Study: 16084255

Group type: EXPERIMENTAL
Intervention: Management with PAC (n=519)
Number of subjects: 1041

Group type: COMPARATOR
Intervention: Management without PAC (n=522)
Number of subjects: 1041
Study: 11839628

Group type: EXPERIMENTAL
Intervention: ADAM10 protein expression during AF
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ADAM15 protein expression during AF
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ADAM15 mRNA expression during AF
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ADAM/integrin ratios in patients with AF
Number of subjects: 30
Study: 10077706

Group type: EXPERIMENTAL
Intervention: Free supplementary insurance for complementary medicine
Number of subjects: 7500

Group type: COMPARATOR
Intervention: Control group (no supplementary insurance)
Number of subjects: 7500
Study: 7574745

Group type: EXPERIMENTAL
Intervention: Continuous arterial infusion of CDDP (10 mg/body) and 5-FU (250 mg/body) for 5 days, with 4 courses administered
Number of subjects: 22

Group type: COMPARATOR
Intervention: Continuous arterial infusion of CDDP and 5-FU for 24 hours
Number of subjects: 22
Study: 2076713

Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (25 mg daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perindopril and Hydrochlorothiazide (combined)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perindopril alone
Number of subjects: 0
Study: 6818864

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 0
Study: 31914241

Group type: EXPERIMENTAL
Intervention: Luspatercept (1.0 up to 1.75 mg/kg, subcutaneously every 3 weeks)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Placebo (subcutaneously every 3 weeks)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Luspatercept
Number of subjects: 229

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study: 29182039

Group type: EXPERIMENTAL
Intervention: Goishi tea polyphenols (122 mg of polyphenols daily)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo (12.2 mg of polyphenols daily)
Number of subjects: 77
Study: 27129137

Group type: EXPERIMENTAL
Intervention: 25-gauge needle with a core trap (ProCore)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Standard 25-gauge needle
Number of subjects: 214
Study: 24722960

Group type: EXPERIMENTAL
Intervention: 6-month telephone-based health coaching intervention (11 sessions using acceptance and commitment therapy strategies)
Number of subjects: 410
Study: 23579543

Group type: EXPERIMENTAL
Intervention: Billroth II reconstruction (n = 52)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Roux-en-Y reconstruction (n = 49)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Billroth II reconstruction
Number of subjects: 101

Group type: COMPARATOR
Intervention: Roux-en-Y reconstruction
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Patients with DGE
Number of subjects: 101

Group type: COMPARATOR
Intervention: Patients without DGE
Number of subjects: 101
Study: 20210904

Group type: EXPERIMENTAL
Intervention: Football group (FG) - trained 2.4 times/week for 12 weeks and 1.3 sessions/week for 52 weeks
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (CG) - no intervention
Number of subjects: 17
Study: 19028953

Group type: EXPERIMENTAL
Intervention: Self-taken pharyngeal swabs for GC
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Self-taken rectal swabs for GC
Number of subjects: 272

Group type: COMPARATOR
Intervention: Nurse-taken pharyngeal swabs for GC
Number of subjects: 272

Group type: COMPARATOR
Intervention: Nurse-taken rectal swabs for GC
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Self-taken rectal swabs for CT
Number of subjects: 272

Group type: COMPARATOR
Intervention: Nurse-taken rectal swabs for CT
Number of subjects: 272
Study: 16909964

Group type: EXPERIMENTAL
Intervention: Raltitrexed 3 mg/m2 every 3 weeks and mitomycin-C 7 mg/m2 every 6 weeks for up to 24 weeks
Number of subjects: 22
Study: 12816777

Group type: EXPERIMENTAL
Intervention: Dried peas (meal 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of dried peas and potatoes (meal 2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Potatoes (meal 3)
Number of subjects: 0
Study: 10849894

Group type: COMPARATOR
Intervention: Single oral dose of valproic acid (800 mg) administered at 8:00 PM
Number of subjects: 12

Group type: COMPARATOR
Intervention: Single oral dose of valproic acid (800 mg) administered at 5:00 AM
Number of subjects: 12
Study: 10423609

Group type: EXPERIMENTAL
Intervention: 10 mg quinapril once daily
Number of subjects: 131

Group type: COMPARATOR
Intervention: 12.5 mg captopril twice daily
Number of subjects: 131
Study: 1347260

Group type: COMPARATOR
Intervention: Metoprolol (100 mg d-1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol (80 mg day-1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol (80-480 mg)
Number of subjects: 0
Study: 4029018

Group type: EXPERIMENTAL
Intervention: Temocillin 1g intravenously
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Temocillin 1g intramuscularly
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (non-functioning gallbladders)
Number of subjects: 15
Study: 30426896

Group type: EXPERIMENTAL
Intervention: Combined intravenous and intraperitoneal chemotherapy
Number of subjects: 49

Group type: COMPARATOR
Intervention: Intravenous chemotherapy
Number of subjects: 49
Study: 27634943

Group type: EXPERIMENTAL
Intervention: Resistance training intervention (3 times per week, 60 min per session for 16 weeks)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Resistance training intervention
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Post-intervention follow-up
Number of subjects: 37
Study: 24438771

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (vitamin D) supplementation for 20 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo medication
Number of subjects: 30
Study: 23726933

Group type: EXPERIMENTAL
Intervention: Pragmatic intervention (n=49) including pharmaceutical management, multimodal physiotherapy, and psychology for post-traumatic stress.
Number of subjects: 101

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 101
Study: 19830704

Group type: EXPERIMENTAL
Intervention: Treatment A (specific treatment not mentioned)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment B (specific treatment not mentioned)
Number of subjects: 0
Study: 17961561

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 50

Group type: COMPARATOR
Intervention: Recombinant FSH
Number of subjects: 50
Study: 16013019

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Number of subjects: 18

Group type: COMPARATOR
Intervention: THAM
Number of subjects: 18
Study: 12973582

Group type: EXPERIMENTAL
Intervention: Pragmatic clinical trials
Number of subjects: 0
Study: 10536544

Group type: EXPERIMENTAL
Intervention: Lidocaine 200 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8800823

Group type: EXPERIMENTAL
Intervention: Co-ordination group (nurse coordinators assisting patients)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Co-ordination group
Number of subjects: 167

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 167
Study: 2070206

Group type: EXPERIMENTAL
Intervention: Neo-adjuvant intravenous cisplatin therapy
Number of subjects: 255

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 255
Study: 6421424

Group type: EXPERIMENTAL
Intervention: Human ultralente insulin
Number of subjects: 18

Group type: COMPARATOR
Intervention: Beef ultralente insulin
Number of subjects: 18
Study: 30130421

Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 203

Group type: COMPARATOR
Intervention: No-CPAP treatment
Number of subjects: 203
Study: 29053848

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 143
Study: 27067467

Group type: EXPERIMENTAL
Intervention: Adductor Canal Catheter (ACC)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Intraarticular Catheter (IAC)
Number of subjects: 96
Study: 24962451

Group type: EXPERIMENTAL
Intervention: Brief motivational interviewing by lay health-care workers (LHCWs)
Number of subjects: 409

Group type: COMPARATOR
Intervention: Brief smoking cessation advice from a TB nurse (control group)
Number of subjects: 409
Study: 22879203

Group type: EXPERIMENTAL
Intervention: Finasteride treatment
Number of subjects: 1247

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1247
Study: 20236631

Group type: EXPERIMENTAL
Intervention: hMG+CC
Number of subjects: 230

Group type: COMPARATOR
Intervention: hMG alone
Number of subjects: 230
Study: 23350617

Group type: EXPERIMENTAL
Intervention: PCL-1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: PCL-2
Number of subjects: 40
Study: 16168485

Group type: EXPERIMENTAL
Intervention: Sharp optic edge PMMA intraocular lens
Number of subjects: 32

Group type: COMPARATOR
Intervention: Round optic edge PMMA intraocular lens
Number of subjects: 32
Study: 12507837

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (CIPX) + Metronidazole (MTR)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Ceftriaxone (CTRX) + Metronidazole (MTR)
Number of subjects: 135
Study: 10772195

Group type: EXPERIMENTAL
Intervention: Indomethacin and betamethasone (group A)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Indomethacin alone (group B)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Betamethasone (group C)
Number of subjects: 29

Group type: COMPARATOR
Intervention: No treatment (group D)
Number of subjects: 29
Study: 8787365

Group type: EXPERIMENTAL
Intervention: Maternal recall of tetanus toxoid vaccination
Number of subjects: 1477
Study: 2058612

Group type: EXPERIMENTAL
Intervention: Dopamine infusion at 1.0 micrograms/kg/min for 72 hours
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Dopamine infusion at 2.5 micrograms/kg/min for 72 hours
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no dopamine)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Dopamine infusion (both doses)
Number of subjects: 49
Study: 6222636

Group type: EXPERIMENTAL
Intervention: FK 33-824 (0.5 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: FK 33-824 (2 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29187304

Group type: EXPERIMENTAL
Intervention: Online supermarket shopping for 3 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual grocery store shopping for 3 months
Number of subjects: 0
Study: 28281112

Group type: EXPERIMENTAL
Intervention: Kymerax© Precision‐Drive Articulating Surgical System
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional laparoscopic instruments (TLI)
Number of subjects: 45
Study: 26614599

Group type: EXPERIMENTAL
Intervention: Coffee consumption (<1 cup/day)
Number of subjects: 90317

Group type: EXPERIMENTAL
Intervention: Coffee consumption (1 cup/day)
Number of subjects: 90317

Group type: EXPERIMENTAL
Intervention: Coffee consumption (2-3 cups/day)
Number of subjects: 90317

Group type: EXPERIMENTAL
Intervention: Coffee consumption (4-5 cups/day)
Number of subjects: 90317

Group type: EXPERIMENTAL
Intervention: Coffee consumption (≥6 cups/day)
Number of subjects: 90317

Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee
Number of subjects: 90317

Group type: EXPERIMENTAL
Intervention: Coffee additives
Number of subjects: 90317

Group type: EXPERIMENTAL
Intervention: Coffee consumption
Number of subjects: 90317
Study: 23467551

Group type: EXPERIMENTAL
Intervention: Mometasone furoate in MLE cream
Number of subjects: 175

Group type: COMPARATOR
Intervention: Methylprednisolone aceponate cream
Number of subjects: 175
Study: 21926653

Group type: EXPERIMENTAL
Intervention: PureVision Low Add
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: PureVision High Add
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Focus Progressives
Number of subjects: 10

Group type: COMPARATOR
Intervention: Single vision lens
Number of subjects: 10
Study: 18670308

Group type: EXPERIMENTAL
Intervention: Larotaxel (50 mg/m) + cisplatin (75 mg/m) every 3 weeks (arm A)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Larotaxel (60 mg/m) + gemcitabine (800 mg/m) every 3 weeks (arm B)
Number of subjects: 62
Study: 16756691

Group type: EXPERIMENTAL
Intervention: Bright-light therapy combined with sertraline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dim-light therapy combined with sertraline
Number of subjects: 0
Study: 12834132

Group type: EXPERIMENTAL
Intervention: Static stretching before and after each physical training session (518 recruits)
Number of subjects: 901

Group type: COMPARATOR
Intervention: Non-stretching (383 recruits)
Number of subjects: 901
Study: 10994859

Group type: EXPERIMENTAL
Intervention: Dipyridamole 0.142 mg/kg x min
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 12
Study: 8865952

Group type: EXPERIMENTAL
Intervention: 4-Methylpyrazole (4-MP) at doses of 10 to 20 mg/kg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ethanol (0.6 g/kg followed by 0.2 g/kg twice)
Number of subjects: 16
Study: 1514885

Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen (60 to 264 micrograms per day)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen
Number of subjects: 3
Study: 6137168

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg
Number of subjects: 0
Study: 30518334

Group type: EXPERIMENTAL
Intervention: Oral Fosfomycin-Trometamol 3000 mg (3 g every 24 h) for 10 days
Number of subjects: 240

Group type: COMPARATOR
Intervention: Ciprofloxacin 500 mg every 12 h for 10 days (standard of care)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Oral Fosfomycin-Trometamol
Number of subjects: 240

Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 240
Study: 27413136

Group type: EXPERIMENTAL
Intervention: 24-h urine collection (initial sample)
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: 24-h urine collection (second sample)
Number of subjects: 476

Group type: COMPARATOR
Intervention: Overall response rate for NHANES examination
Number of subjects: 476
Study: 23294470

Group type: EXPERIMENTAL
Intervention: DBBM with tibial BMA (N = 6)
Number of subjects: 13

Group type: COMPARATOR
Intervention: DBBM without tibial BMA (N = 6)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: DBBM with iliac BMAC (N = 7)
Number of subjects: 13

Group type: COMPARATOR
Intervention: DBBM without iliac BMAC (N = 7)
Number of subjects: 13
Study: 23242297

Group type: EXPERIMENTAL
Intervention: Periodontal intervention (subgingival scaling and planing ultrasonic and manual)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (supragingival prophylaxis)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 57
Study: 20697090

Group type: EXPERIMENTAL
Intervention: Fludarabine (F)
Number of subjects: 375

Group type: COMPARATOR
Intervention: Fludarabine + cyclophosphamide (FC)
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: TP53 mutation
Number of subjects: 375

Group type: COMPARATOR
Intervention: FC treatment arm
Number of subjects: 375
Study: 18299900

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 53
Study: 16841663

Group type: EXPERIMENTAL
Intervention: Three ways method of acupuncture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hand and foot acupuncture
Number of subjects: 60
Study: 12372571

Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 298

Group type: COMPARATOR
Intervention: PTCR
Number of subjects: 298
Study: 10459590

Group type: EXPERIMENTAL
Intervention: Active Compression-Decompression (ACD) CPR
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard (STD) CPR
Number of subjects: 90
Study: 7485874

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway
Number of subjects: 18

Group type: COMPARATOR
Intervention: Facemask
Number of subjects: 18
Study: 2272259

Group type: COMPARATOR
Intervention: Radiation alone (R)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Hyperthermia alone (H)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Combination of hyperthermia and radiation (RH)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Combination of hyperthermia and radiation (HR)
Number of subjects: 5
Study: 6936555

Group type: EXPERIMENTAL
Intervention: Variable diameter dental floss
Number of subjects: 15

Group type: COMPARATOR
Intervention: Conventional unwaxed dental floss
Number of subjects: 15
Study: 30548170

Group type: EXPERIMENTAL
Intervention: Glycolic acid peel
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Microneedling with dermapen
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination of glycolic acid peel and microneedling
Number of subjects: 30
Study: 28699041

Group type: EXPERIMENTAL
Intervention: Pulse Rate Variability (PRV) analysis
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Pulse Transit Time (PTT) analysis
Number of subjects: 51
Study: 25646170

Group type: EXPERIMENTAL
Intervention: SRP with application of 810 nm diode laser and ICG at a concentration of 5 mg/mL
Number of subjects: 30

Group type: COMPARATOR
Intervention: SRP with application of 810 nm diode laser
Number of subjects: 30

Group type: COMPARATOR
Intervention: SRP
Number of subjects: 30
Study: 23824419

Group type: EXPERIMENTAL
Intervention: GH administration
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 22106300

Group type: EXPERIMENTAL
Intervention: Equitable decision making
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inequitable decision making
Number of subjects: 0
Study: 19284928

Group type: EXPERIMENTAL
Intervention: Olanzapine/Fluoxetine Combination (OFC)
Number of subjects: 1146

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 1146

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 1146
Study: 17442584

Group type: EXPERIMENTAL
Intervention: Gabapentin (GP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Naproxen Sodium (NS)
Number of subjects: 40
Study: 15715103

Group type: EXPERIMENTAL
Intervention: Radiotherapy in conjunction with roentgeno‐endovascular occlusion of the internal ileal arteries and/or regional chemotherapy
Number of subjects: 308

Group type: COMPARATOR
Intervention: Standard combined therapy
Number of subjects: 308
Study: 11441134

Group type: EXPERIMENTAL
Intervention: G-to-T transversion at the first nucleotide of exon 5 causing G154V missense mutation
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: T-to-C transition in the invariant GT at position +2 of the 5' donor splice site of intron 8
Number of subjects: 1
Study: 9471039

Group type: EXPERIMENTAL
Intervention: Volume-adjusted prostate-specific antigen (PSAT)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Total prostate volume PSA (PSA)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Total prostate volume PSA density (PSAD)
Number of subjects: 61
Study: 8543959

Group type: EXPERIMENTAL
Intervention: Ascorbic acid 500 mg twice daily
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group received 10 mg of ascorbic acid twice daily
Number of subjects: 88
Study: 2164194

Group type: EXPERIMENTAL
Intervention: Mitomycin C/Ifosfamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mitomycin C/Vindesine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisplatin/Etoposide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 373099

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 15

Group type: COMPARATOR
Intervention: Bendrofluazide (thiazide diuretic)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Atenolol and Bendrofluazide combined
Number of subjects: 15

Group type: COMPARATOR
Intervention: Bendrofluazide
Number of subjects: 15
Study: 31149704

Group type: EXPERIMENTAL
Intervention: CrAg screening plus 4-weekly home visits for adherence support
Number of subjects: 1999

Group type: COMPARATOR
Intervention: Standard clinic-based care
Number of subjects: 1999

Group type: EXPERIMENTAL
Intervention: CrAg screening plus adherence support
Number of subjects: 1999
Study: 27744438

Group type: EXPERIMENTAL
Intervention: Vaginal probiotics with antibiotic prophylaxis
Number of subjects: 106

Group type: COMPARATOR
Intervention: Antibiotics only
Number of subjects: 106
Study: 26152495

Group type: EXPERIMENTAL
Intervention: Immediate post-test (IPT)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Delayed post-test (DPT)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Self-assessed certainty (Definitely) during IPT
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Self-assessed certainty (Definitely) during DPT
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Choosing Definitely over Probably
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Interaction between test timing and certainty
Number of subjects: 115